[go: up one dir, main page]

FI974060L - Sulfatoitujen oligosakkaridien valmistus ja käyttö - Google Patents

Sulfatoitujen oligosakkaridien valmistus ja käyttö Download PDF

Info

Publication number
FI974060L
FI974060L FI974060A FI974060A FI974060L FI 974060 L FI974060 L FI 974060L FI 974060 A FI974060 A FI 974060A FI 974060 A FI974060 A FI 974060A FI 974060 L FI974060 L FI 974060L
Authority
FI
Finland
Prior art keywords
preparation
sulfated oligosaccharides
sulfated
oligosaccharides
Prior art date
Application number
FI974060A
Other languages
English (en)
Swedish (sv)
Other versions
FI974060A0 (fi
FI974060A7 (fi
Inventor
Christopher Rickhard Parish
William Butler Cowden
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3786969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI974060(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Australian filed Critical Univ Australian
Publication of FI974060A0 publication Critical patent/FI974060A0/fi
Publication of FI974060A7 publication Critical patent/FI974060A7/fi
Publication of FI974060L publication Critical patent/FI974060L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
FI974060A 1995-04-28 1996-04-24 Sulfatoitujen oligosakkaridien valmistus ja käyttö FI974060L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN2618A AUPN261895A0 (en) 1995-04-28 1995-04-28 Preparation and use of sulfated oligosaccharides
PCT/AU1996/000238 WO1996033726A1 (en) 1995-04-28 1996-04-24 Preparation and use of sulfated oligosaccharides

Publications (3)

Publication Number Publication Date
FI974060A0 FI974060A0 (fi) 1997-10-27
FI974060A7 FI974060A7 (fi) 1997-10-27
FI974060L true FI974060L (fi) 1997-10-27

Family

ID=3786969

Family Applications (1)

Application Number Title Priority Date Filing Date
FI974060A FI974060L (fi) 1995-04-28 1996-04-24 Sulfatoitujen oligosakkaridien valmistus ja käyttö

Country Status (26)

Country Link
US (1) US6143730A (fi)
EP (1) EP0837683B1 (fi)
JP (2) JP4514240B2 (fi)
KR (1) KR100591960B1 (fi)
CN (1) CN1090021C (fi)
AT (1) ATE463250T1 (fi)
AU (1) AUPN261895A0 (fi)
BR (1) BR9608041B8 (fi)
CA (1) CA2218872C (fi)
CZ (1) CZ341097A3 (fi)
DE (1) DE69638158D1 (fi)
EA (1) EA001199B1 (fi)
EE (1) EE9700277A (fi)
ES (1) ES2341924T3 (fi)
FI (1) FI974060L (fi)
HU (1) HUP9802394A2 (fi)
IL (1) IL118047A (fi)
IS (1) IS4596A (fi)
NO (1) NO974911L (fi)
NZ (1) NZ305815A (fi)
PL (1) PL184357B1 (fi)
PT (1) PT837683E (fi)
TR (1) TR199701264T1 (fi)
TW (1) TW446710B (fi)
WO (1) WO1996033726A1 (fi)
ZA (1) ZA963339B (fi)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO556297A0 (en) * 1997-03-11 1997-04-10 Australian National University, The Sulfated oligosaccharides having anticoagulant/ antithrombotic activity
DK1014996T3 (da) * 1997-08-28 2003-09-29 Univ Washington Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
AUPO888497A0 (en) * 1997-09-01 1997-09-25 Australian National University, The Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
AUPO976897A0 (en) * 1997-10-14 1997-11-06 Australian National University, The Use of sulfated oligosaccharides in lowering blood triglyceride levels
GB9802725D0 (en) * 1998-02-09 1998-04-08 Ciba Geigy Ag Organic compounds
US7132402B2 (en) * 1998-11-24 2006-11-07 Wyeth Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
US7081448B2 (en) * 1998-11-24 2006-07-25 Wyeth Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB0001481D0 (en) * 2000-01-21 2000-03-15 Theryte Ltd System for delivering a medicament
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
FR2808687B1 (fr) * 2000-04-27 2003-12-05 Goemar Lab Sa Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose
JP4676048B2 (ja) * 2000-07-10 2011-04-27 生化学工業株式会社 脱髄性疾患処置剤
US7407773B2 (en) * 2000-11-03 2008-08-05 Procognia, Ltd. Method for characterizing a carbohydrate polymer
TW519716B (en) * 2000-12-19 2003-02-01 Tokyo Electron Ltd Wafer bias drive for a plasma source
EP1353556A4 (en) 2001-01-23 2009-09-09 Massachusetts Inst Technology SYNTHESIS OF HEPARIN AND OTHER GLYCOSAMINOGLYCANS IN SOLID PHASE AND SOLUTION PHASE
CN1394867A (zh) * 2001-07-06 2003-02-05 中国科学院生态环境研究中心 可作药物的寡糖和其制备方法及含该寡糖的药物组合物
PT2343077E (pt) 2001-09-12 2013-08-29 Sigma Tau Res Switzerland Sa Derivados de glicosaminoglicanos totalmente n-dessulfatados como inibidores da heparanase, capazes de atividade antiangiogénica e desprovidos de efeito anticoagulante
KR20030046810A (ko) * 2001-12-06 2003-06-18 은삼제약 주식회사 콘드로이친 황산의 분해산물을 포함하는 관절염 예방 또는치료용 약학적 조성물
AUPS052802A0 (en) * 2002-02-15 2002-03-07 Praxis Pharmaceuticals International Pty Ltd Carbohydrate-based anti-wrinkle and tissue remodelling compounds
CA2478700C (en) 2002-03-11 2012-10-16 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US20040161476A1 (en) * 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
WO2005054493A2 (en) * 2003-06-12 2005-06-16 Mayo Foundation For Medical Education And Research Altered activity of toll-like receptors
CN1989146A (zh) * 2004-03-04 2007-06-27 普罗吉恩工业有限公司 硫酸化寡聚糖衍生物
JP5404406B2 (ja) * 2006-10-20 2014-01-29 ジ オーストラリアン ナショナル ユニバーシティ 細胞外マトリクスの分解の阻害
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
DK2164501T3 (en) * 2007-05-31 2016-05-30 Paradigm Biopharmaceuticals Ltd Sulfated xylans for the treatment or prophylaxis of respiratory diseases
EP2170259B1 (en) * 2007-06-28 2018-09-05 BASF Beauty Care Solutions France SAS Slimming composition
FR2917971B1 (fr) 2007-06-28 2009-10-23 Engelhard Lyon Soc Par Actions Composition amincissante
US8153611B2 (en) * 2007-06-28 2012-04-10 Basf Beauty Care Solutions France S.A.S. Use of sulfated oligosaccharides as slimming cosmetic ingredients
CN104666318A (zh) 2007-10-16 2015-06-03 普罗吉恩制药有限公司 新的硫酸化寡糖衍生物
US20100266558A1 (en) * 2007-12-18 2010-10-21 Dov Zipori Method and assay for glycosylation pattern detection related to cell state of stem cells
RU2538973C2 (ru) * 2008-05-30 2015-01-10 Момента Фармасьютикалз, Инк. Структуры сахаридов и способы получения и применения таких структур
EP2149580A1 (en) 2008-07-15 2010-02-03 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Mimetics of sulfated oligosaccharides
US8809009B2 (en) 2009-01-02 2014-08-19 Biomarin Pharmaceutical Inc. Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
US8592140B2 (en) 2009-01-02 2013-11-26 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
GB0915315D0 (en) * 2009-09-03 2009-10-07 Univ Manchester Use of non-digestible oligosaccharides
JP5701498B2 (ja) * 2009-12-01 2015-04-15 公益財団法人微生物化学研究会 炎症性細胞からのヘパラナーゼの放出抑制剤、抗炎症剤、及び薬用組成物
EP2526122B1 (en) * 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2011122321A1 (ja) * 2010-03-29 2011-10-06 国立大学法人名古屋大学 ヘパリン結合性蛋白に対する生理活性阻害剤
ES2710857T3 (es) * 2010-12-01 2019-04-29 Univ Australian National Uso de polianiones para inhibir la actividad citotóxica de las histonas en el tratamiento de la sepsis
WO2012112953A2 (en) * 2011-02-18 2012-08-23 President And Fellows Of Harvard College Molecular switch for neuronal outgrowth
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN102199175A (zh) * 2011-04-07 2011-09-28 福州大学 硫酸类肝素二糖的制备纯化方法及其纯化产品
EP2722049A4 (en) * 2011-06-09 2014-12-10 Medigen Biotechnology Corp PHARMACEUTICAL COMPOSITION FOR INHIBITING REZIDIVE, CLOSING AND METASTASES OF A LIVER CARCINOMA
US20130209444A1 (en) * 2012-01-30 2013-08-15 Baxter Healthcare S.A. Non-anticoagulant sulfated or sulfonated polysaccharides
CN105408361B (zh) * 2013-05-16 2019-09-06 新加坡科技研究局 硫酸乙酰肝素
AU2015255823A1 (en) 2014-05-08 2016-11-10 Immunexcite, Inc. Immunomodulating beta-1,6-D-glucans
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
CZ306662B6 (cs) * 2015-06-26 2017-04-26 Contipro A.S. Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
JP2016199579A (ja) * 2016-07-08 2016-12-01 基亜生物科技股▲ふん▼有限公司Ｍｅｄｉｇｅｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． 肝癌の再発、悪化または転移の抑制に用いる医薬組成物
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
WO2018107200A1 (en) 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
EP3723862A4 (en) * 2017-12-12 2021-08-25 Academia Sinica OCTASACCHARIDES AND THEIR USES
WO2019113646A1 (en) * 2017-12-15 2019-06-20 Griffith University Sulfation method
JP6619830B2 (ja) * 2018-02-22 2019-12-11 基亜生物科技股▲ふん▼有限公司Ｍｅｄｉｇｅｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． 肝癌の再発、悪化または転移の抑制に用いる医薬組成物
NL2024493B1 (en) * 2019-12-16 2021-09-02 Logick Energetics B V Pharmaceutical composition for preventing or stopping metastases
WO2021125951A1 (en) 2019-12-18 2021-06-24 Logick Energetics B.V. Pharmaceutical composition for use in preventing or stopping metastases
CN110917208B (zh) * 2019-12-27 2021-02-12 浙江医院 硫酸化甘露葡萄糖醛酸六糖在防治动脉粥样硬化中的应用
CN111904968A (zh) * 2020-08-21 2020-11-10 青岛市中心医院 硫酸半乳四糖及其衍生物在制备抗上皮细胞黏附药物中的应用
CN113633658A (zh) * 2021-07-09 2021-11-12 南京理工大学 硫酸葡半乳寡聚糖在制备抗凝血和/或抗血栓药物中的应用
CN114134188B (zh) * 2021-07-23 2023-03-17 光明乳业股份有限公司 一种发酵小麦麸皮合成胞外多糖的方法
CN115646378A (zh) * 2022-09-15 2023-01-31 哈尔滨工业大学 一种生物质胶质凝胶及其制备方法、应用
CN116650425B (zh) * 2023-07-13 2025-06-27 晟迪生物医药(苏州)有限公司 糖酯化合物或其盐在冷冻保护、冷冻干燥保护中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869530B (en) * 1985-12-24 1987-10-28 Marion Laboratories Inc Use of synthetic sulfated saccharides to enhance wound healing
FR2597484B1 (fr) * 1986-04-17 1988-12-23 Sanofi Sa Glycosaminoglycanes de type heparine ou heparane-sulfate dotes d'une activite sur la division et la differentiation cellulaires, leur preparation et leurs applications therapeutiques.
US5541166A (en) * 1987-01-23 1996-07-30 The Australian National University Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity
WO1989003684A1 (fr) * 1987-10-30 1989-05-05 Chugai Seiyaku Kabushiki Kaisha Agent anti-vih
US5506210A (en) * 1988-08-19 1996-04-09 The Australian National University Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
JPH0296588A (ja) * 1988-09-29 1990-04-09 Rikagaku Kenkyusho 硫酸化オリゴ糖及びその関連物質
JP2956090B2 (ja) * 1989-10-30 1999-10-04 大日本インキ化学工業株式会社 オリゴ糖誘導体
CA2071915A1 (en) * 1990-08-23 1992-02-24 Tadao Shoji Antiviral agent
CA2061370A1 (en) * 1991-03-13 1992-09-14 Markus Hosang Pharmaceutical preparations
WO1992018546A1 (en) * 1991-04-17 1992-10-29 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5459257A (en) * 1993-01-11 1995-10-17 Dainippon Ink And Chemicals, Inc. Sulfated oligoglycoside acylate and antiviral agent containing the same as active ingredient
JPH06256373A (ja) * 1993-01-11 1994-09-13 Dainippon Ink & Chem Inc 硫酸化オリゴ糖配糖体アシル化物およびこれを有効成分とする抗ウイルス剤
FR2710741B1 (fr) * 1993-09-30 1995-10-27 Commissariat Energie Atomique Capteur électronique destiné à la caractérisation de grandeurs physiques et procédé de réalisation d'un tel capteur.
US5739115A (en) * 1993-10-07 1998-04-14 Glycomed Incorporated Sulfated maltooligosaccharides with heparin-like properties
WO1995009637A1 (en) * 1993-10-07 1995-04-13 Glycomed Incorporated Highly sulfated maltooligosaccharides with heparin-like properties

Also Published As

Publication number Publication date
EP0837683A1 (en) 1998-04-29
NO974911L (no) 1997-12-29
IL118047A0 (en) 1996-08-04
CA2218872A1 (en) 1996-10-31
IL118047A (en) 2000-11-21
CN1183043A (zh) 1998-05-27
EE9700277A (et) 1998-04-15
CN1090021C (zh) 2002-09-04
NO974911D0 (no) 1997-10-24
AUPN261895A0 (en) 1995-05-18
FI974060A0 (fi) 1997-10-27
US6143730A (en) 2000-11-07
BR9608041B8 (pt) 2014-11-18
PT837683E (pt) 2010-07-09
TW446710B (en) 2001-07-21
PL184357B1 (pl) 2002-10-31
PL323080A1 (en) 1998-03-02
WO1996033726A1 (en) 1996-10-31
JP2009235085A (ja) 2009-10-15
BR9608041A (pt) 1999-01-26
NZ305815A (en) 1999-05-28
HUP9802394A2 (hu) 1999-02-01
EA001199B1 (ru) 2000-12-25
JP4514240B2 (ja) 2010-07-28
EP0837683A4 (en) 2007-07-04
EP0837683B1 (en) 2010-04-07
ATE463250T1 (de) 2010-04-15
IS4596A (is) 1997-10-21
FI974060A7 (fi) 1997-10-27
ES2341924T3 (es) 2010-06-29
TR199701264T1 (xx) 1998-02-21
CZ341097A3 (cs) 1998-03-18
KR100591960B1 (ko) 2007-12-04
MX9708289A (es) 1998-06-30
DE69638158D1 (de) 2010-05-20
CA2218872C (en) 2007-02-20
EA199700347A1 (ru) 1998-06-25
KR19990008198A (ko) 1999-01-25
BR9608041B1 (pt) 2012-02-22
ZA963339B (en) 1997-01-03
JPH11504018A (ja) 1999-04-06

Similar Documents

Publication Publication Date Title
FI974060L (fi) Sulfatoitujen oligosakkaridien valmistus ja käyttö
FI973750L (fi) 2-metyylitienobentsodiatsepiinin valmistus ja kiteiset muodot
FI973163L (fi) Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)-desetyylioksibutyniiniä
PT1093815E (pt) Formulacao oral de 2-metil-tieno-benzodiazepina
FI20000516A7 (fi) Bis-indolyylimaleimidijohdannaiset ja niiden valmistus
FI973447A7 (fi) Sulkimen ja injektioruiskun yhdistelmä
BR8901779A (pt) Absorvente higienico e metodo de aplicacao do mesmo
DE69623914D1 (de) Äusserliches hautpräparat
PT832104E (pt) Derivados de dolastatina sua preparacao e utilizacao
BR9609831A (pt) Composições cosméticas e/ou farmacêuticas antipruríticas
BR9606984A (pt) Vassoura e conjunto de vassoura
KR970000228A (ko) S-에토돌락의 경구용 제제
BR9502691A (pt) Uso de ácido hialurônico e dispositivo protético
DE69620642D1 (de) Reiningungsverfahren und-zusammensetzung
PT874854E (pt) Antibioticos de cefalosporina
NO965564D0 (no) Medisinsk anvendelse av bromelain
ZA96610B (en) Preparation of n-aryl and n-hetaryhydroxylamines
FI960585A7 (fi) Oligosakkaridien käyttö kudosvanhenemisen ehkäisemiseksi ja hoitamisek si
ID19147A (id) Ksilanase dan pemakaiannya
PT1025100E (pt) Derivados de tetra-hidropiridopirimidona substituidos na posicao 3 sua preparacao e sua utilizacao
FI963325A7 (fi) Inhibiinikoostumukset ja menetelmät niiden käyttämiseksi
FI913552A7 (fi) Haaroituneen lohko-kopolymeerin valmistus ja käyttö
FI943642L (fi) Sulfatoidut polysakkaridit, menetelmä niiden valmistamiseksi, farmaseuttinen valmistus ja käyttö
BR9609081A (pt) Combinações de substáncias ativas
ID18913A (id) Turunan turunan tienopiridin dan penggunaannya